IMS Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-806
| Closed | -$7K | – | 156 |
|
|
2022
Q1 | $7K | Hold |
806
| – | – | ﹤0.01% | 140 |
|
|
2021
Q4 | $9K | Hold |
806
| – | – | ﹤0.01% | 137 |
|
|
2021
Q3 | $14K | Buy |
806
+400
| +99% | +$6.6K | 0.01% | 134 |
|
|
2021
Q2 | $8K | Hold |
406
| – | – | ﹤0.01% | 130 |
|
|
2021
Q1 | $10K | Buy |
+406
| New | +$12.2K | 0.01% | 123 |
|
|
2020
Q1 | – | Sell |
-31
| Closed | -$5K | – | 147 |
|
|
2019
Q4 | $5K | Buy |
+31
| New | +$7.71K | ﹤0.01% | 132 |
|
|
2019
Q3 | – | Sell |
-39
| Closed | -$22K | – | 139 |
|
|
2019
Q2 | $22K | Hold |
39
| – | – | 0.02% | 123 |
|
|
2019
Q1 | $45K | Hold |
39
| – | – | 0.04% | 115 |
|
|
2018
Q4 | $35K | Sell |
39
-3
| -7% | -$4.35K | 0.03% | 117 |
|
|
2018
Q3 | $64K | Buy |
42
+9
| +27% | +$13.3K | 0.04% | 180 |
|
|
2018
Q2 | $42K | Hold |
33
| – | – | 0.03% | 167 |
|
|
2018
Q1 | $481K | Hold |
33
| – | – | 0.3% | 84 |
|
|
2017
Q4 | $481K | Buy |
33
+7
| +27% | +$162K | 0.3% | 84 |
|
|
2017
Q3 | $731K | Buy |
26
+5
| +24% | +$154K | 0.47% | 67 |
|
|
2017
Q2 | $1.06M | Sell |
21
-2
| -9% | -$109K | 1% | 31 |
|
|
2017
Q1 | $1.77M | Hold |
23
| – | – | 1.77% | 8 |
|
|
2016
Q4 | $1.79M | Hold |
23
| – | – | 1.92% | 6 |
|
|
2016
Q3 | $2.9M | Buy |
23
+6
| +35% | +$749K | 3.34% | 3 |
|
|
2016
Q2 | $1.87M | Buy |
17
+3
| +21% | +$353K | 2.19% | 5 |
|
|
2016
Q1 | $1.89M | Buy |
14
+1
| +8% | +$107K | 2.29% | 7 |
|
|
2015
Q4 | $1.78M | Buy |
13
+1
| +8% | +$149K | 2.19% | 6 |
|
|
2015
Q3 | $2.01M | Buy |
12
+3
| +33% | +$701K | 2.41% | 4 |
|
|
2015
Q2 | $2.71M | Buy |
+9
| New | +$2.38M | 3.22% | 2 |
|
Other funds holding NVIV
TRCT
IA
IMS Capital Management's NVIV Position: Q2 2022 in Review
IMS Capital Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2022, closing a stake of 806 shares — an estimated $7K sold.
IMS Capital Management first reported a position in NVIV in Q2 2015 and held it in 23 quarters. The position peaked at $2.9M in Q3 2016. 13 funds tracked by Wall St. Rank hold NVIV as of Q2 2022.
- IMS Capital Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2022 after selling out during the quarter.
- IMS Capital Management sold 806 InVivo Therapeutics Holdings Corp shares in Q2 2022, an estimated $7K.
- IMS Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 23 quarters.
- IMS Capital Management's InVivo Therapeutics Holdings Corp position peaked at $2.9M in Q3 2016.
- 13 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2022.
Based on IMS Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.